IP Verse

Ready-To-Use Bortezomib Solution - EP3324937B1

PatentPatent Analysis

EP3324937

STADA ARZNEIMITTEL
Application Number
EP16744351A
Filing Date
Jul 21, 2016
Status
Granted And Under Opposition
Jul 15, 2022
Grant Date
Aug 17, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3324936B1
EP1591105B1
EP2233127B1

Bibliography

The patent EP3324937B1 was granted to Stada Arzneimittel on Aug 17, 2022 following the initial filing on Jul 21, 2016 under the application number EP16744351A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREMay 17, 2023ADMISSIBLE
EXTROVISMay 16, 2023ADMISSIBLE
NEDERLANDSCH OCTROOIBUREAUMay 16, 2023ADMISSIBLE
GRUNDMay 15, 2023ADMISSIBLE
STRAWMANMay 12, 2023ADMISSIBLE
CONSILIENT HEALTHApr 24, 2023ADMISSIBLE
EVER VALINJECTAug 18, 2022ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents